Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 766-97-2 Chemical Structure| 766-97-2

Structure of 4-Ethynyltoluene
CAS No.: 766-97-2

Chemical Structure| 766-97-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Rodriguez, Diego F. ; Duran-Osorio, Francisca ; Duarte, Yorley ; Olivares, Pedro ; Moglie, Yanina ; Dua, Kamal , et al.

Abstract: Green chemistry implementation has led to promising results in waste reduction in the pharmaceutical industry. However, the early sustainable development of pharmaceutically active compounds and ingredients remains a considerable challenge. Herein, we wish to report a green synthesis of new pharmaceutically active peptide triazoles as potent factor Xa inhibitors, an important drug target associated with the treatment of diverse cardiovascular diseases. The new inhibitors were synthesized in three steps, featuring cycloaddition reactions (high atom economy), microwave-assisted organic synthesis (energy efficiency), and copper nanoparticle catalysis, thus featuring Earth-abundant metals. The molecules obtained showed FXa inhibition, with IC50-values as low as 17.2 μM and no associated cytotoxicity in HEK293 and HeLa cells. These results showcase the environmental potential and chemical implications of the applied methodologies for the development of new molecules with pharmacological potential.

Keywords: DOACs ; FXa inhibitors ; Ullmann-Goldberg reaction ; click chemistry ; drug discovery ; green chemistry ; microwave synthesis

Purchased from AmBeed: ; ; ;

Krzysztof Kuciński ; Grzegorz Hreczycho ;

Abstract: Commercially available and inexpensive potassium bis(trimethylsilyl)amide (KHMDS) serves as an efficient transition metal-free catalyst for the catalytic sp C−H silylation of several terminal alkynes including two pharmaceuticals. Overall, the presented system allows the synthesis of various attractive silylacetylenes under mild conditions, making this approach an environmentally benign and sustainable alternative to existing synthetic solutions.

Alternative Products

Product Details of [ 766-97-2 ]

CAS No. :766-97-2
Formula : C9H8
M.W : 116.16
SMILES Code : CC1=CC=C(C#C)C=C1
MDL No. :MFCD00008571
InChI Key :KSZVOXHGCKKOLL-UHFFFAOYSA-N
Pubchem ID :13018

Safety of [ 766-97-2 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H225-H302+H312+H332-H315-H319-H335
Precautionary Statements:P241-P242-P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362+P364-P370+P378-P374-P380-P501
Class:3
UN#:3295
Packing Group:

Computational Chemistry of [ 766-97-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 6
Fraction Csp3 0.11
Num. rotatable bonds 0
Num. H-bond acceptors 0.0
Num. H-bond donors 0.0
Molar Refractivity 39.34
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

0.0 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.28
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

3.03
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.06
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

4.08
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.96
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.88

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.96
Solubility 0.127 mg/ml ; 0.00109 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.7
Solubility 0.234 mg/ml ; 0.00202 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.81
Solubility 0.179 mg/ml ; 0.00154 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

Low
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-4.86 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.57

Application In Synthesis of [ 766-97-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 766-97-2 ]

[ 766-97-2 ] Synthesis Path-Downstream   1~54

  • 1
  • [ 577-91-3 ]
  • [ 129397-83-7 ]
  • [ 108-24-7 ]
  • [ 766-97-2 ]
  • 4-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-2-phenyl-ethyl]-2,6-bis-(4-methylphenyl)ethynyl-phenyl acetate [ No CAS ]
  • 2
  • [ 129397-83-7 ]
  • [ 108-24-7 ]
  • [ 452282-75-6 ]
  • [ 766-97-2 ]
  • 4-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)ethyl]-2-methoxy-6-(4-methylphenyl)-ethynyl-phenyl acetate [ No CAS ]
  • 3
  • [ 201230-82-2 ]
  • [ 577-91-3 ]
  • [ 129397-83-7 ]
  • [ 628-89-7 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-2-phenyl-ethyl]-2-(4-methylphenyl)-7-(4-methylphenyl)ethynyl-benzofuran-3-carboxylic acid, 2-(2-chloro-ethoxy)-ethyl ester [ No CAS ]
  • 4
  • [ 201230-82-2 ]
  • [ 129397-83-7 ]
  • [ 628-89-7 ]
  • [ 452282-75-6 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-ethyl]-7-methoxy-2-(4-methylphenyl)-benzo[b]furan-3-carboxylic acid, 2-(2-chloro-ethoxy)-ethyl ester [ No CAS ]
  • 5
  • [ 201230-82-2 ]
  • [ 577-91-3 ]
  • [ 129397-83-7 ]
  • [ 504-63-2 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-2-phenyl-ethyl]-2-(4-methoxyphenyl)-7-(4-methylphenyl)ethynyl-benzofuran-3-carboxylic acid, 3-hydroxypropyl ester [ No CAS ]
  • 6
  • [ 201230-82-2 ]
  • [ 129397-83-7 ]
  • [ 452282-75-6 ]
  • [ 504-63-2 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-ethyl]-7-methoxy-2-(4-methylphenyl)-benzo[b]furan-3-carboxylic acid, 3-hydroxy-propyl ester [ No CAS ]
  • 7
  • [ 201230-82-2 ]
  • [ 577-91-3 ]
  • [ 129397-83-7 ]
  • [ 111-46-6 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-2-phenyl-ethyl]-2-(4-methylphenyl)-7-(4-methylphenyl)ethynyl-benzofuran-3-carboxylic acid, 2-(2-hydroxy-ethoxy)-ethyl ester [ No CAS ]
  • 8
  • [ 201230-82-2 ]
  • [ 129397-83-7 ]
  • [ 452282-75-6 ]
  • [ 111-46-6 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-ethyl]-7-methoxy-2-(4-methylphenyl)-benzo[b]furan-3-carboxylic acid, 2-(2-hydroxy-ethoxy)-ethyl ester [ No CAS ]
  • 9
  • [ 821-41-0 ]
  • [ 201230-82-2 ]
  • [ 577-91-3 ]
  • [ 129397-83-7 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-2-phenyl-ethyl]-2-(4-methylphenyl)-7-(4-methylphenyl)ethynyl-benzofuran-3-carboxylic acid, hex-5-enyl ester [ No CAS ]
  • 10
  • [ 821-41-0 ]
  • [ 201230-82-2 ]
  • [ 129397-83-7 ]
  • [ 452282-75-6 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-ethyl]-7-methoxy-2-(4-methylphenyl)-benzo[b]furan-3-carboxylic acid hex-5-enyl ester [ No CAS ]
  • 11
  • [ 111-29-5 ]
  • [ 201230-82-2 ]
  • [ 577-91-3 ]
  • [ 129397-83-7 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-2-phenyl-ethyl]-2-(4-methylphenyl)-7-(4-methylphenyl)ethynyl-benzofuran-3-carboxylic acid, 5-hydroxypentyl ester [ No CAS ]
  • 12
  • [ 111-29-5 ]
  • [ 201230-82-2 ]
  • [ 129397-83-7 ]
  • [ 452282-75-6 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-ethyl]-7-methoxy-2-(4-methylphenyl)-benzo[b]furan-3-carboxylic acid, 5-hydroxy-pentyl ester [ No CAS ]
  • 13
  • [ 629-11-8 ]
  • [ 201230-82-2 ]
  • [ 577-91-3 ]
  • [ 129397-83-7 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-2-phenyl-ethyl]-2-(4-methylphenyl)-7-(4-methylphenyl)ethynyl-benzofuran-3-carboxylic acid, 6-hydroxyhexyl ester [ No CAS ]
  • 14
  • [ 629-11-8 ]
  • [ 201230-82-2 ]
  • [ 129397-83-7 ]
  • [ 452282-75-6 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-ethyl]-7-methoxy-2-(4-methylphenyl)-benzo[b]furan-3-carboxylic acid, 6-hydroxyhexyl ester [ No CAS ]
  • 15
  • [ 64-17-5 ]
  • [ 201230-82-2 ]
  • [ 577-91-3 ]
  • [ 129397-83-7 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-2-phenyl-ethyl]-2-(4-methylphenyl)-7-(4-methylphenyl)ethynyl-benzofuran-3-carboxylic acid, ethyl ester [ No CAS ]
  • 16
  • [ 64-17-5 ]
  • [ 201230-82-2 ]
  • [ 129397-83-7 ]
  • [ 452282-75-6 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-ethyl]-7-methoxy-2-(4-methylphenyl)-benzo[b]furan-3-carboxylic acid ethyl ester [ No CAS ]
  • 17
  • [ 75-89-8 ]
  • [ 201230-82-2 ]
  • [ 577-91-3 ]
  • [ 129397-83-7 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-2-phenyl-ethyl]-2-(4-methylphenyl)-7-(4-methylphenyl)ethynyl-benzofuran-3-carboxylic acid, 2,2,2-trifluoro-ethyl ester [ No CAS ]
  • 18
  • [ 75-89-8 ]
  • [ 201230-82-2 ]
  • [ 129397-83-7 ]
  • [ 452282-75-6 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-ethyl]-7-methoxy-2-(4-methylphenyl)-benzo[b]furan-3-carboxylic asid, 2,2,2-trifluoro-ethyl ester [ No CAS ]
  • 19
  • [ 201230-82-2 ]
  • [ 5406-18-8 ]
  • [ 577-91-3 ]
  • [ 129397-83-7 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-2-phenyl-ethyl]-2-(4-methylphenyl)-7-(4-methylphenyl)ethynyl-benzofuran-3-carboxylic acid, 3-(4-methoxy-phenyl)-propyl ester [ No CAS ]
  • 20
  • [ 201230-82-2 ]
  • [ 5406-18-8 ]
  • [ 129397-83-7 ]
  • [ 452282-75-6 ]
  • [ 766-97-2 ]
  • 5-[2-(1-(S)-benzyl-2-hydroxy-ethylcarbamoyl)-ethyl]-7-methoxy-2-(4-methylphenyl)-benzo[b]furan-3-carboxylic acid 3-(4-methoxy-phenyl)-propyl ester [ No CAS ]
  • 21
  • [ 4316-94-3 ]
  • [ 766-97-2 ]
  • 5-nitro-6-<i>p</i>-tolylethynyl-pyrimidin-4-ylamine [ No CAS ]
  • 22
  • [ 615-43-0 ]
  • [ 766-97-2 ]
  • [ 55577-25-8 ]
YieldReaction ConditionsOperation in experiment
74% General procedure: A dry sealed tube was charged with 1.1 mmol (271 mg) of 2-iodoaniline and 2 equiv. of K3PO4 (424 mg). To the above mixture was added 1 mmol of phenylacetylene (102 mg, 0.109 ml), 5 mol % of Et2Zn (0.05 ml), 10 mol % of DMEDA (0.01 ml) and 3 ml of acetonitrile under nitrogen. The sealed tube was heated in an oil bath which was preheated to 125 C and the reaction mixture was stirred under the same conditions for 12 hours. After that 2 equiv. of NaOtBu (192 mg) was added to the reaction mixture and allowed to stir for another six hours. The reaction mixture was then cooled and extracted with ethyl acetate (3 x 15 ml) and the ethyl acetate layer was washed with distilled water. The organic layer was dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure in a rotary evaporator. The crude residue was purified by column chromatography using hexane as the eluent to get 172 mg (89 %) of the product as a colourless solid. All other benzofuran derivatives were synthesized by similar procedure.
  • 23
  • [ 121554-10-7 ]
  • [ 766-97-2 ]
  • [ 880499-55-8 ]
  • 24
  • [ 83410-37-1 ]
  • [ 766-97-2 ]
  • [ 929880-37-5 ]
  • 25
  • [ 615-37-2 ]
  • [ 766-97-2 ]
  • 1-(2-(4-methylphenyl)ethynyl)-2-methylbenzene [ No CAS ]
YieldReaction ConditionsOperation in experiment
92% With C22H20Cl4N4O2PdS; potassium carbonate; In ethanol; at 80℃; for 1h; General procedure: K2CO3 (2.5 × 10-4 mol, 2.5 equiv), aryl iodide (1.0 × 10-4 mol, 1.0 equiv), and alkyne (1.5 × 10-4 mol, 1.5 equiv) were mixed in a 10-mL vial, followed by addition of a solution of the selected catalyst (1 × 10-8 mol) in EtOH (1 mL). The vial was placed in a preheated oil bath at 80 C and stirred for 1 h. After cooling to 20-25 C, the reaction mixture was evaporated to dryness under a stream of dinitrogen followed by addition of 1.0 equiv of 1,2-dimethoxyethane as NMR internal standard, and extraction of the reaction mixture with three 0.20-mL portions of CDCl3. All fractions were joined and analyzed by 1H NMR spectroscopy. The product peak assignments were based on the authentic samples or on published dat, whereas quantifications were performed upon integration of the selected peak of the product relatively to the peak of the standard.
  • 26
  • [ 23784-96-5 ]
  • [ 766-97-2 ]
  • [ 1235527-72-6 ]
  • 28
  • [ 18163-47-8 ]
  • [ 766-97-2 ]
  • [ 130248-74-7 ]
  • 29
  • [ 16066-09-4 ]
  • [ 766-97-2 ]
  • 2,5-dimethyl-3-(p-tolyl)-2,5-bis((trimethylsilyl)oxy)-2,5-dihydro-1,2,5-oxadisilole [ No CAS ]
  • 2,5-dimethyl-3-(p-tolyl)-2,5-bis((trimethylsilyl)oxy)-2,5-dihydro-1,2,5-oxadisilole [ No CAS ]
  • 30
  • [ 6214-35-3 ]
  • [ 766-97-2 ]
  • 5-[1-p-Tolyl-meth-(Z)-ylidene]-5H-furan-2-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
82% With copper(l) iodide; palladium 10% on activated carbon; triethylamine; triphenylphosphine; In 1,4-dioxane; at 25 - 80℃; for 3.5h;Inert atmosphere; General procedure: (a) The reaction was performed in a bigger scale using 100 mg of 10% Pd/C (0.092 mmol), PPh3 (0.37 mmol), CuI (0.184 mmol), Et3N (10.68 mmol), compound 1a (3.56 mmol), and acetylenic compound 2a (5.32 mmol) in 1,4-dioxane (20.0 mL). After stirring at 80 C for 3 h under nitrogen the mixture was cooled to room temperature. The Pd/C was filtered off and washed with water (2 10 mL), acetone (2 10 mL), and EtOAc (2 10 mL). Then the catalyst was collected, dried at 100 C in an oven, and reused for the next run. The co-catalyst CuI along with PPh3 was added in every repeated run. (b) General method for the preparation of 3: A mixture of compound 1 (0.89 mmol), 10% Pd/C (0.023 mmol), PPh3 (0.092 mmol), CuI (0.046 mmol), and Et3N (2.67 mmol) in 1,4-dioxane (5.0 mL) was stirred at 25 C for 30 min under nitrogen. The acetylenic compound 2 (1.33 mmol) was added slowly with stirring. The mixture was then stirred at 80 C for 3 h, cooled to room temperature, diluted with EtOAc (30 mL), and filtered through celite. The filtrate was collected and concentrated. The residue was purified by column chromatography (2-15% EtOAc/hexane) to afford the desired product
  • 31
  • [ 67247-13-6 ]
  • [ 766-97-2 ]
  • [ 1430210-20-0 ]
  • 32
  • [ 67247-13-6 ]
  • [ 766-97-2 ]
  • [ 1430209-76-9 ]
  • 33
  • [ 173676-59-0 ]
  • [ 766-97-2 ]
  • [ 1456900-24-5 ]
  • 34
  • [ 111771-08-5 ]
  • [ 766-97-2 ]
  • 8-fluoro-3-p-tolyl-1H-isochromen-1-one [ No CAS ]
  • 35
  • [ 2568-25-4 ]
  • [ 103-49-1 ]
  • [ 766-97-2 ]
  • α-[(4-methylphenyl)ethynyl]-N,N-bis(phenylmethyl)benzenemethanamine [ No CAS ]
YieldReaction ConditionsOperation in experiment
50% With indium(III) chloride; In toluene;Inert atmosphere; Reflux; General procedure: Acetal (1.2 mmol), alkyne (1.2 mmol), dibenzylamine (0.192 mL,1.0 mmol), and InCl3 (10 molpercent) were added to a flask (25 mL), followedby the addition of toluene (2.0 mL) under argon. The mixture was stirredunder reflux and monitored by TLC. The solution was then cooled to r.t.,diluted with dichloromethane (5.0 mL), washed with brine. The aqueouslayer was extracted with CH2Cl2 (3 × 10 mL), the combined organic layer was dried over MgSO4, filtered, and evaporated under vacuum. Theresidue was purified by column chromatography on silica gel (petroleumether) to afford the desired product.
  • 36
  • [ 99768-12-4 ]
  • [ 766-97-2 ]
  • [ 792-74-5 ]
  • 37
  • [ 109466-87-7 ]
  • [ 109-73-9 ]
  • [ 766-97-2 ]
  • C21H19F3N2 [ No CAS ]
  • 38
  • [ 175278-00-9 ]
  • [ 766-97-2 ]
  • C16H11F3O [ No CAS ]
  • 39
  • [ 30309-80-9 ]
  • [ 766-97-2 ]
  • di-o-tolyl(p-tolylethynyl)phosphine oxide [ No CAS ]
  • 40
  • [ 75676-72-1 ]
  • [ 766-97-2 ]
  • 2-chloro-1-methoxy-4-(p-tolylethynyl)benzene [ No CAS ]
  • 41
  • [ 19591-17-4 ]
  • [ 766-97-2 ]
  • 1-(2-(p-tolyl)-1H-indol-1-yl)ethanone [ No CAS ]
YieldReaction ConditionsOperation in experiment
73% With potassium phosphate; diethylzinc; N,N`-dimethylethylenediamine; In acetonitrile; at 125℃; for 12h;Sealed tube; Inert atmosphere; General procedure: A dry sealed tube was charged with 1.1 mmol (271 mg) of 2-iodophenol and 2 equiv. of K3PO4 (424 mg). To the above mixture was added 1 mmol of phenylacetylene (102 mg, 0.109 ml), 5 mol % of Et2Zn (0.05 ml), 10 mol % of DMEDA (0.01 ml) and 3 ml of acetonitrile under nitrogen. The sealed tube was heated in an oil bath which was preheated to 125 C and the reaction mixture was stirred under the same conditions for 12 hours. The reaction mixture was then cooled and extracted with ethyl acetate (3 x 15 ml) and the ethyl acetate layer was washed with distilled water. The organic layer was dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure in a rotary evaporator. The crude residue was purified by column chromatography using hexane as the eluent to get 180 mg (93 %) of the product as a colourless solid. All other benzofuran derivatives were synthesized by similar procedure.
  • 42
  • [ 201230-82-2 ]
  • [ 3032-81-3 ]
  • [ 623-51-8 ]
  • [ 766-97-2 ]
  • ethyl 3-(3,5-dichlorophenyl)-5-(p-tolyl)thiophene-2-carboxylate [ No CAS ]
  • 43
  • [ 42019-78-3 ]
  • [ 766-97-2 ]
  • 4-(1-(4-chlorophenyl)-1-hydroxy-3-(p-tolyl)prop-2-yn-1-yl)phenol [ No CAS ]
  • 44
  • [ 42019-78-3 ]
  • [ 766-97-2 ]
  • (S)-4-(1-(4-chlorophenyl)-3-(p-tolyl)prop-2-yn-1-yl)phenol [ No CAS ]
  • 45
  • [ 615-43-0 ]
  • [ 766-97-2 ]
  • [ 16112-21-3 ]
  • 46
  • [ 38573-88-5 ]
  • [ 766-97-2 ]
  • 8-fluoro-2-(p-tolyl)-4H-thiochromen-4-one [ No CAS ]
  • 47
  • [ 119072-55-8 ]
  • [ 38573-88-5 ]
  • [ 766-97-2 ]
  • C20H19F2N [ No CAS ]
YieldReaction ConditionsOperation in experiment
With palladium diacetate; caesium carbonate; bis[2-(diphenylphosphino)phenyl] ether; In N,N-dimethyl-formamide; at 100℃; for 2h;Sealed tube; Inert atmosphere; General procedure: In a 15 mL sealed tube equipped with a magnetic stirring bar were added 1 (1 mmol),2 (0.8 mmol), tert-butyl isocyanide (1.2 mmol, 136 muL), Pd(OAc)2 (0.03 mmol, 7 mg),DPEPhos (0.06 mmol, 32 mg), Cs2CO3 (0.8 mmol, 261 mg), and anhydrous DMF (2.0mL). The tube was purged with argon, and the contents were stirred at 100 °C for 2 h.Then Na2S*9H2O (1.2 mmol, 240 mg) was added for 2 h. After reaction completion,the mixture was filtered through a pad of Celite, and DMF was removed by a vacuum.The combined filtrates were refluxed in THF (15 mL) and oxalic acid (1 M, 3 mL) for 8h. The solvents were removed under reduced pressure, then poured into brine (20mL) and extracted by ethyl acetate (3 × 30 mL). The combined organic layers weredried (Na2SO4) and evaporated. The residue was purified on a silica gel column usingpetroleum ether/ethyl acetate as the eluent to give the pure target product.
  • 48
  • [ 54413-93-3 ]
  • [ 766-97-2 ]
  • [ 1283669-14-6 ]
  • 49
  • [ 1006-33-3 ]
  • [ 766-97-2 ]
  • C17H13FO [ No CAS ]
  • 50
  • [ 26767-16-8 ]
  • [ 766-97-2 ]
  • 1-(2-bromophenyl)-4-(p-tolyl)but-3-yne-1,2-dione [ No CAS ]
  • 51
  • [ 40263-57-8 ]
  • [ 766-97-2 ]
  • 2-(4-tolyl)-furo[3,2-b]pyridine [ No CAS ]
YieldReaction ConditionsOperation in experiment
58% With potassium phosphate; C43H36N4O4Pd; In dimethylsulfoxide-d6; at 90℃; for 10h; General procedure: In a typical run, performed in air, a 25 mL of round bottom askwas charged with a mixture of 2-iodophenol (0.50 mmol), terminalalkyne (0.60 mmol), and K3PO4 (1.00 mmol). A palladium complex(2a or 2b, 0.0005 mmol) was added to the mixture, followed byDMSO (ca. 2 mL) as a solvent, and then the reaction mixture washeated (either at 90C or at 120C) for 10 h. The reaction mixturewas cooled to room temperature, and water (ca. 20 mL) was added.The resulting mixture was extracted with EtOAc (ca. 50 mL). Theorganic layer was further extracted with EtOAc (ca. 2 20 mL). Theorganic layers were combined and vacuum dried to obtain a crudeproduct that was subsequently puried by column chromatog-raphy. The obtained benzofuran derivatives (3aa3ap) were char-acterized by NMR and Mass spectroscopy (See SupportingInformation Figures S4-S23).
  • 52
  • [ 689291-89-2 ]
  • [ 766-97-2 ]
  • 1-(5-bromo-2-iodophenyl)-3-(p-tolyl)prop-2-yn-1-one [ No CAS ]
  • 53
  • [ 766-97-2 ]
  • [ 4079-54-3 ]
  • 54
  • [ 136812-21-0 ]
  • [ 766-97-2 ]
  • 8-methyl-2-(p-tolylethynyl)quinoline-3-carbonitrile [ No CAS ]
 

Historical Records

Categories